Currently out of the existing stock ratings of Jason Zemansky, 9 are a BUY (50%), 8 are a HOLD (44.44%), 1 are a SELL (5.56%).

Jason Zemansky

Work Performance Price Targets & Ratings Chart

Analyst Jason Zemansky works at BAML with a stock forecast success ratio of 33.33% fulfilled within 49.5 days on average.

Jason Zemansky’s has documented 34 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ESPR, Esperion Therapeutics at 03-Jan-2024.

Wall Street Analyst Jason Zemansky

Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 3/16/2023. The price target of $1.5 was fulfilled within 6 days with a profit of $0.32 (17.58%) receiving and performance score of 29.3.

Average potential price target upside

ALLK Allakos CYTK Cytokinetics ESPR Esperion Therapeutics INSM Insmed HOWL Werewolf Therapeutics RCUS Arcus Biosciences

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

1

$-0.34 (-25.37%)

1.5

1 months 7 days ago

4/6 (66.67%)

$-1.99 (-66.56%)

371

Buy

1.5

$0.16 (11.94%)

9

1 months 7 days ago

3/4 (75%)

$-1.49 (-49.83%)

119

Buy

3

$1.66 (123.88%)

1 months 7 days ago

0/2 (0%)

$0.01 (0.33%)

Buy

2 months 6 days ago

1/1 (100%)

$32.69 (83.16%)

358

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jason Zemansky is most bullish on?

Potential upside of $9.72 has been obtained for INSM (INSMED)

Which stock is Jason Zemansky is most reserved on?

Potential downside of -$0 has been obtained for ESPR (ESPERION THERAPEUTICS)

What Year was the first public recommendation made by Jason Zemansky?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?